Showing results for:
Asparaginase erwinia chrysanthemi
Asparaginase Erwinia chrysanthemi is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.
Erwinaze® Asparaginase Erwinia chrysanthemi
Deferasirox is FDA approved to remove excess iron that is in the body because of blood transfusions. Deferasirox works by attaching to iron molecules in the body so they can be excreted (removed from the body) in feces.Deferasirox is indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. This indication is approved under accelerated approval based on a reduction of liver iron concentrations and serum ferritin levels. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Exjade® Jadenu® Deferasirox
Rolvedon is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
Rolvedon™ Eflapegrastim-xnst
Elotuzumab is FDA approved for the treatment of multiple myelomaIn combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Empliciti™ Elotuzumab
Elranatamab-bcmm is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Elranatamab-bcmm
Enasidenib (Idhifa®) is FDA approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay, which is used to detect specific mutations in the IDH2 gene in patients with AML.
Idhifa® Enasidenib
Epcoritamab-bysp is indicated for the treatment of Diffuse Large B-cell Lymphoma and High-grade B-cell LymphomaAdult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapyFollicular LymphomaAdult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy
Epcoritamab-bysp Epkinly®
Epoetin alfa is indicated forTreatment of anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapyReduction of allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery.Epogen is not indicated for use:In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapyIn patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cureIn patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusionIn patients scheduled for surgery who are willing to donate autologous bloodIn patients undergoing cardiac or vascular surgeryAs a substitute for RBC transfusions in patients who require immediate correction of anemia
Epogen® Procrit® EPO Epoetin alfa Epoetin alfa-epbx* Retacrit™ *
Etoposide is used to treat people who have certain types of blood cancer including Hodgkin and non-Hodgkin lymphoma. It is FDA approved for some types of lung and testicular cancer. This medicine often causes a temporary loss of hair. After treatment with etoposide has ended, normal hair growth should return.
Etopophos® Toposar® VePesid® VP-16 Etoposide
U.S. Food and Drug Administration (FDA) has granted approval of EVOMELA for use in two indications:Use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation (ASCT) in patients with multiple myeloma (MM)For the palliative treatment of patients with MM for whom oral therapy is not appropriate.This is the first product to be FDA-approved for the high-dose conditioning indication in MM.
Evomela™ Melphalan hydrochloride
Rasburicase is FDA approved for the initial management of plasma uric acid levels in patients with leukemia, lymphoma and solid tumors who are receiving certain types of anticancer therapy expected to result in elevated plasma uric acid.
Elitek® Rasburicase
Tagraxofusp-erzs is FDA approved for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients two years and older.
Elzonris™ Tagraxofusp-erzs